185 related articles for article (PubMed ID: 11154006)
1. Bisphosphonate therapy in fibrous dysplasia.
Lane JM; Khan SN; O'Connor WJ; Nydick M; Hommen JP; Schneider R; Tomin E; Brand J; Curtin J
Clin Orthop Relat Res; 2001 Jan; (382):6-12. PubMed ID: 11154006
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Chapurlat RD; Delmas PD; Liens D; Meunier PJ
J Bone Miner Res; 1997 Oct; 12(10):1746-52. PubMed ID: 9333137
[TBL] [Abstract][Full Text] [Related]
3. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
[TBL] [Abstract][Full Text] [Related]
4. Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density.
Weinstein RS
J Bone Miner Res; 1997 Aug; 12(8):1314-5. PubMed ID: 9258763
[No Abstract] [Full Text] [Related]
5. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia.
Parisi MS; Oliveri B; Mautalen CA
Bone; 2003 Oct; 33(4):582-8. PubMed ID: 14555262
[TBL] [Abstract][Full Text] [Related]
6. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
Heijckmann AC; Juttmann JR; Wolffenbuttel BH
Neth J Med; 2002 Sep; 60(8):315-9. PubMed ID: 12481878
[TBL] [Abstract][Full Text] [Related]
7. Medical therapy in adults with fibrous dysplasia of bone.
Chapurlat RD
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P114-9. PubMed ID: 17228999
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Liens D; Delmas PD; Meunier PJ
Lancet; 1994 Apr; 343(8903):953-4. PubMed ID: 7909013
[TBL] [Abstract][Full Text] [Related]
9. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
10. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
Plotkin H; Rauch F; Zeitlin L; Munns C; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2003 Oct; 88(10):4569-75. PubMed ID: 14557424
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for the treatment of fibrous dysplasia of bone.
Chapurlat R; Legrand MA
Bone; 2021 Feb; 143():115784. PubMed ID: 33276154
[TBL] [Abstract][Full Text] [Related]
12. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
Pfeilschifter J; Ziegler R
Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942
[TBL] [Abstract][Full Text] [Related]
13. Oral alendronate treatment for polyostotic fibrous dysplasia: a case report.
Kitagawa Y; Tamai K; Ito H
J Orthop Sci; 2004; 9(5):521-5. PubMed ID: 15449129
[TBL] [Abstract][Full Text] [Related]
14. The nonsurgical treatment of fibrous dysplasia.
Chapurlat R; Meunier PJ
Rev Rhum Engl Ed; 1999 Jan; 66(1):1-3. PubMed ID: 10036690
[No Abstract] [Full Text] [Related]
15. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
[TBL] [Abstract][Full Text] [Related]
16. Use of high-dose oral bisphosphonate therapy for symptomatic fibrous dysplasia of the skull.
Chao K; Katznelson L
J Neurosurg; 2008 Nov; 109(5):889-92. PubMed ID: 18976079
[TBL] [Abstract][Full Text] [Related]
17. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
Lala R; Matarazzo P; Bertelloni S; Buzi F; Rigon F; de Sanctis C
Acta Paediatr; 2000 Feb; 89(2):188-93. PubMed ID: 10709889
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate therapy for fibrous dysplasia.
DiMeglio LA
Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():440-5. PubMed ID: 17982393
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
